In highly chemo-resistant neuroblastoma cells HTLA-230, treatment with bortezomib (BTZ), the first selective and reversible 26S proteasome inhibitor, led to Nrf2 activation, thus reducing the expected improvement in cell chemosensitivity. Here, NFE2L2 is linked to neuroblastoma.